Western Alliance Bancorp Stock Plunges on First Brands Fallout — Analysts See Upside

Western Alliance Bancorp Stock Plunges on First Brands Fallout — Analysts See Upside

  • Western Alliance (NYSE: WAL) traded around $78–79 in mid‑October 2025 [1], off from its 52-week high near $98 (one-year range $57–$98 [2]). Analysts’ 12‑month target is roughly $100–105, implying ~30–35% upside [3] [4].
  • Shares slumped in early October after news of exposure to bankrupt auto-supplier First Brands Group. A Jefferies fund had about $715M tied to First Brands receivables, sparking fear of losses for Western Alliance [5] [6]. The stock dropped ~4% on Oct 8 on this news [7], and was still down ~5–6% by Oct 16 [8].
  • JPMorgan and other analysts have upgraded WAL. JPMorgan’s Anthony Elian raised his price target to $105 with an Overweight rating [9]. RBC Capital boosted its target to $100 (Outperform) on Oct 10 [10]. Consensus is Strong Buy (14 Buys, 1 Sell) with average target ≈$103 [11] [12].
  • Western Alliance reports Q3 2025 earnings on Oct 21 (after market). Analysts expect about $2.11 EPS on ~$891M revenue for Q3 [13] (up from $1.91 EPS and $718M in Q2). Meeting estimates could lift the stock if worries over First Brands abate.
  • The wider U.S. banking sector is upbeat: major banks just reported strong Q3 results (record trading and solid net interest income) [14] [15], bolstering confidence in banks. For example, JPMorgan and BofA exceeded forecasts with high trading revenues and NII [16].

Stock Trends and Recent Moves

Western Alliance’s stock has been volatile recently. After rallying through summer, it tumbled in early October. On Oct 8, WAL fell about 4% amid headlines that a Jefferies-managed fund (Point Bonita) held ~$715 million in First Brands receivables [17] [18]. By Oct 15, WAL closed near $78.84, down ~4% for the day [19]. Trading volume surged as investors digested the news. A day later (Oct 16), Reuters reported WAL shares were still down ~5.4% [20], despite the bank’s reassurances. Management disclosed it had filed a fraud lawsuit related to one credit and said its “criticized assets” (weak loans) actually fell from June to Sept [21]. These efforts helped “pare losses” on Oct 16 [22], but the stock remained well below recent highs. (For context, Western Alliance’s 52-week range is about $57 to $98 [23].)

First Brands Bankruptcy Exposure

The sharp swing is largely driven by First Brands Group’s collapse. First Brands, an auto-parts supplier, filed Chapter 11 in late Sept with $10–$50 billion of liabilities [24]. TS2 Tech reported that First Brands immediately drew $1.1 billion in DIP financing to keep running [25]. Crucially, First Brands had quietly amassed large off-balance-sheet debts and had sold factored receivables to finance buyers. Jefferies was First Brands’ main lender for years; its Point Bonita fund holds roughly $715M of First Brands–backed receivables [26] – nearly 25% of that fund’s $3B portfolio. These receivables were supposed to be payments from major retailers (Walmart, AutoZone, etc.) that First Brands sold; but First Brands stopped forwarding customer payments in mid-September [27].

News of this “vanished” debt spooked investors. Western Alliance itself didn’t loan directly to First Brands, but its involvement via Jefferies triggered fear of spillover. Analysts note that in a worst-case, Western Alliance’s hit should be limited – Jefferies says it’s working “diligently” to protect Point Bonita [28]. Indeed, reports suggest Jefferies’ own losses may be “manageable” given its small direct equity in the fund [29]. Western Alliance management stressed that its direct credit problems have not worsened: the bank said its total weak loans are actually lower than last quarter [30]. In short, the First Brands saga highlights risks in opaque credit webs, but so far Western Alliance’s balance sheet appears solid.

Analyst Commentary and Forecasts

Wall Street analysts have largely taken a cautious-but-bullish stance. JPMorgan analyst Anthony Elian maintained an Overweight rating and lifted his 12‑month price target to $105 [31]. He cites Western Alliance’s strong deposit initiatives and growing net interest income. Similarly, RBC Capital bumped its target to $100 (Outperform) in early Oct [32]. TD Cowen and National Bankshares have also set lofty targets (~$118) with Buy ratings in late Sept [33]. Overall, 13 of 14 covering analysts are positive, and the consensus 12‑month target is about $103–104 [34] [35] (about 30–35% above current levels). MarketBeat notes analysts expect ~$9.05 EPS for 2025 (full year) [36].

Some analysts have even downplayed the First Brands scare. A Seeking Alpha author summarized that Jefferies’ disclosures imply any WAL losses should be “unlikely to cause material losses” [37]. Indeed, with Western Alliance trading at a premium to book but still below historical valuations, the stock could rebound if these fears prove overblown. The coming Q3 results (Oct 21 after market) will be critical. Analysts forecast about $2.11 EPS on roughly $891M revenue [38] – both solid year-over-year gains. If WAL meets or beats estimates and words downplay credit concerns, analysts expect the stock to climb.

Banking Sector & Peer Trends

Western Alliance’s moves come as the broader banking sector looks strong. In mid-October, major banks reported surprisingly robust results: JP Morgan, BofA, Morgan Stanley, Wells Fargo, etc., all beat earnings and revenue forecasts [39]. A FinancialContent report noted “a powerful surge” in Q3 earnings across big banks, driven by a rebound in trading and sustained net interest income [40] [41]. This fueled a mini-rally in bank stocks: the KBW regional bank index climbed, and analysts upgraded many big names. Bank stocks’ strength stems from diversified revenues (M&A fees, trading gains) and still-solid lending margins [42].

Nevertheless, Western Alliance faces headwinds and is often lumped with other regionals. For example, in April WAL shares plunged nearly 10% in one day, alongside peers, after tariffs risk hit markets [43]. Likewise, on Oct 16, a Reuters story noted Western Alliance sold off as Zions Bancorp announced a $50 million loan charge-off [44]. Even though Western Alliance was not involved in that particular loss, the episode rattled regional bank sentiment. Such volatility shows that smaller banks can trade on the broad risk environment – interest rate worries, loan quality fears and regulation headlines all matter.

On the flip side, Western Alliance’s fundamentals are sounder than many peers. Its loan growth (targeting billions in new loans), focus on tech/venture clients, and rising deposit initiatives position it for growth [45] [46]. (JPMorgan notes WAL is pushing toward $100B in assets, which could trigger regulatory relief on some rules [47] [48].) Compared to smaller regionals, Western Alliance also boasts a strong capital position and has navigated past shocks fairly well.

Outlook

In summary, Western Alliance’s recent stock swoon is tied mainly to external events (First Brands bankruptcy, broader credit jitters) rather than a sudden deterioration of its own earnings. Investors will be watching the Oct 21 earnings and any further analyst commentary. If results come in line or better – and if fears of hidden losses fade – many analysts see the stock as a buying opportunity. As one recent report puts it, the First Brands exposure “appears overblown,” and Western Alliance could have upsides to the low-$100s per share [49]. However, risks remain: any surprise credit losses or a chill in the economy could weigh on WAL.

Sources: Company filings and press releases; analyst notes; Reuters, Investing.com, Yahoo Finance, MarketBeat, Investopedia, TS2 Tech and other financial media [50] [51] [52] [53] [54] [55] [56] [57].

https://youtube.com/watch?v=ksWLf8Qx5nk

References

1. www.investing.com, 2. www.investing.com, 3. www.investing.com, 4. www.marketbeat.com, 5. ts2.tech, 6. mlq.ai, 7. mlq.ai, 8. www.reuters.com, 9. www.marketbeat.com, 10. www.marketbeat.com, 11. www.marketbeat.com, 12. stockanalysis.com, 13. www.marketbeat.com, 14. markets.financialcontent.com, 15. markets.financialcontent.com, 16. markets.financialcontent.com, 17. ts2.tech, 18. mlq.ai, 19. www.investing.com, 20. www.reuters.com, 21. www.reuters.com, 22. www.reuters.com, 23. www.investing.com, 24. ts2.tech, 25. ts2.tech, 26. ts2.tech, 27. ts2.tech, 28. ts2.tech, 29. ts2.tech, 30. www.reuters.com, 31. www.marketbeat.com, 32. www.marketbeat.com, 33. www.marketbeat.com, 34. www.marketbeat.com, 35. stockanalysis.com, 36. www.marketbeat.com, 37. mlq.ai, 38. www.marketbeat.com, 39. markets.financialcontent.com, 40. markets.financialcontent.com, 41. markets.financialcontent.com, 42. markets.financialcontent.com, 43. www.investopedia.com, 44. www.reuters.com, 45. www.benzinga.com, 46. www.reuters.com, 47. www.benzinga.com, 48. www.benzinga.com, 49. mlq.ai, 50. www.marketbeat.com, 51. www.investing.com, 52. ts2.tech, 53. ts2.tech, 54. markets.financialcontent.com, 55. www.reuters.com, 56. mlq.ai, 57. www.investopedia.com

Stock Market Today

  • Snap Stock Surges 18% on $400 Million Perplexity AI Deal
    November 6, 2025, 7:33 AM EST. Snap (SNAP) jumped 18% in pre-market after beating Q3 revenue estimates and announcing a $500 million stock buyback. Revenue rose to $1.51 billion, above expectations of $1.49B, while daily active users reached 477 million. The company inked a $400 million partnership with AI search startup Perplexity to embed its conversational search into Snapchat, starting in early 2026. The move diversifies revenue beyond ads, though the company warns about potential Q4 headwinds from Apple/Google age-verification changes and Australia's restrictions. Profitability improved, with net losses narrowing over 30% YoY and adjusted EBITDA of $182 million. Analysts' price targets and upside discussions remain mixed amid a year-to-date decline.
  • Is Elevance Health a Hidden Opportunity After a 24.5% Drop in 2025?
    November 6, 2025, 7:28 AM EST. Elevance Health has tumbled in 2025 amid policy shifts and broader healthcare-sector volatility, with a year-to-date drawdown and a longer 24.5% slide that has investors rethinking value. The piece weighs near- and long-term catalysts, noting that a high valuation score isn't translating into certainty as government program changes loom for managed care. The core takeaway is a rigorous DCF assessment, which, using current free cash flow of $3.6B and projected growth, yields an intrinsic value around $1,090.84 per share-roughly 71% above current prices, signaling undervaluation. Still, equity investors should monitor the PE ratio, competitive dynamics, and policy risk, which could affect how quickly this perceived bargain translates into realized gains.
  • Inflammation Biotech Evommune Starts NYSE Trading in $150M IPO
    November 6, 2025, 7:24 AM EST. Evommune is heading to the NYSE with a $150 million IPO to fund two clinical-stage assets. The Palo Alto biopharma is offering 9.3 million shares at $16 each, pricing in the $15-$17 range. Gross proceeds are $150 million, potentially rising by about $22.5 million if underwriters exercise their option for an additional 1.4 million shares. Trading under the ticker EVMN could begin today. The company plans to use the funds to advance two phase 2 programs, including EVO756, an oral MRGPRX2 antagonist being studied for CSU and atopic dermatitis (AD). Topline data for CSU from a phase 2 study showed 93% responses at four weeks. Data for AD topline in H2 2026. Evommune priced amid a broader biotech IPO backdrop as MapLight Therapeutics went public last week.
  • Arm Holdings Stock Surges on Q2 Beat, Strong AI Demand Lifts Outlook
    November 6, 2025, 7:22 AM EST. Arm Holdings (ARM) stock jumps about 5-6% in pre-market trading after reporting a Q2 beat that topped revenue and earnings estimates and issuing stronger Q3 guidance. The company posted revenue of $1.14 billion, up 34% year over year, and EPS of $0.22, exceeds consensus of $0.13. Arm also raised its quarterly revenue guide to about $1.23 billion versus the $1.10 billion expected. Royalty revenue reached a record $620 million, up 21%, led by data centers, automotive, and IoT, with hyperscalers like Google, Amazon, and Microsoft boosting Arm-based deployments. Licensing revenue rose 56% to $515 million. The AI infrastructure buildout underscores demand for Arm's energy-efficient designs, and management hints at potential in-house chip development beyond licensing.
  • Capital One Stock Prediction: Analysts See Up to 29% Upside by 2027 on Discover Acquisition
    November 6, 2025, 7:20 AM EST. Capital One (NYSE: COF) trades around $221 with an average target near $260, implying ~18% upside. Targets span $290 (high) and $210 (low), with a median near $258 and a mix of 14 Buys, 3 Outperforms, and 6 Holds. Growth projections call for revenue up about 19% annually through 2027, supported by operating margins near 48% and a forward multiple around 9.7x. A guided model points to ~$285/share by 2027, or about 29% total upside (12% annualized). The story centers on the Discover acquisition, expanded payments network, and stable credit trends amid solid consumer spending, though conviction remains modest and upside depends on continued earnings growth and credit stability.
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch
Previous Story

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Oracle Stock Surges on $300B AI Cloud Deal – Is a Trillion-Dollar Valuation Next?
Next Story

Oracle Stock Surges on $300B AI Cloud Deal – Is a Trillion-Dollar Valuation Next?

Go toTop